share_log

Trinity Biotech Receives Increased Orders For TrinScreen HIV, Total Orders Received To Date For Supply In 2024 To ~$6M; Increased Its Expected 2024 Sales Revenue For TrinScreen HIV To Over $8M

Benzinga ·  May 13 23:44

Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to approximately $6 million.

The Company has successfully scaled up production to meet the increased demand for its rapid HIV tests.

As a result of this strong momentum in demand and the successful scaling of production capacity, the Company has increased its expected 2024 sales revenue for TrinScreen HIV to over $8 million.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment